Compare Enveric Biosciences Inc (ENVB) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Invesco NASDAQ 100 ETF — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Invesco NASDAQ 100 ETF trades at $308.93 (market cap $113.40B). The key difference: Invesco NASDAQ 100 ETF is far larger — about 16676.5× Enveric Biosciences Inc's market cap, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Invesco NASDAQ 100 ETF for 54 Days on average.
| ENVB | QQQM | |
|---|---|---|
Market Cap | $6.80M | $113.40B |
Volume | 64,867 | 2,866,236 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $312.76 |
52-Week Low | $1.27 | $229.87 |
Typical Hold Time | 14 Days | 54 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
QQQM trades at $308.42, down 1.15% on the day, while maintaining a bullish technical outlook with strong moving average support. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads can impact returns. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026, signaling confidence in the Nasdaq-100 exposure.
The ETF offers pure Nasdaq-100 exposure with competitive fees, though investors should be aware of concentration risk in technology stocks and potential tax implications of distributions. Technical indicators suggest near-term support at $305 with resistance at $311, while institutional accumulation supports the bullish case for long-term growth investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
